As of close of business last night, Aurinia Pharmaceuticals Inc’s stock clocked out at $5.52, down -1.43% from its previous closing price of $5.60. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 1766218 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of AUPH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.99 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.22.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 27 ’24 when Knappertz Volker sold 4,930 shares for $6.10 per share. The transaction valued at 30,073 led to the insider holds 319,128 shares of the business.
Knappertz Volker sold 25,146 shares of AUPH for $137,800 on Feb 20 ’24. The EVP, Research and Development now owns 324,058 shares after completing the transaction at $5.48 per share. On Feb 20 ’24, another insider, Habig Scott Michael, who serves as the Chief Commercial Officer of the company, sold 15,867 shares for $5.48 each. As a result, the insider received 86,951 and left with 492,364 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 808.41M and an Enterprise Value of 555.53M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.55 while its Price-to-Book (P/B) ratio in mrq is 2.10. Its current Enterprise Value per Revenue stands at 3.17 whereas that against EBITDA is -8.81.
Stock Price History:
Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 7.63, while the 200-Day Moving Average is calculated to be 8.78.
Shares Statistics:
It appears that AUPH traded 2.53M shares on average per day over the past three months and 2.69M shares per day over the past ten days. A total of 143.83M shares are outstanding, with a floating share count of 127.57M. Insiders hold about 11.79% of the company’s shares, while institutions hold 36.53% stake in the company. Shares short for AUPH as of Feb 15, 2024 were 16.85M with a Short Ratio of 6.65, compared to 16.39M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.65% and a Short% of Float of 11.69%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.2, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.15 and -$0.34 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.39, with 6 analysts recommending between $0.83 and -$0.14.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $47.45M. It ranges from a high estimate of $51.82M to a low estimate of $46M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $34.41M, an estimated increase of 37.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $232.83M, while the lowest revenue estimate was $207M, resulting in an average revenue estimate of $224.25M. In the same quarter a year ago, actual revenue was $175.51M, up 27.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $288.87M in the next fiscal year. The high estimate is $339.89M and the low estimate is $250M. The average revenue growth estimate for next year is up 28.80% from the average revenue estimate for this year.
